Cramp severity (0 to 10 VAS; higher = more pain) (after 6 weeks) · 50‐ to 60‐year‐old women with metabolic syndrome
1 finding from 1 review
Participants with 1 or more serious adverse events · patients with Guillain‐Barré syndrome
It is very uncertain whether brain‐derived neurotrophic factor changes participants with 1 or more serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
Participants with 1 or more serious adverse events · patients with Guillain‐Barré syndrome
It is very uncertain whether cerebrospinal fluid filtration changes participants with 1 or more serious adverse events compared with plasma exchange (very low certainty).
1 finding from 1 review
Participants with 1 or more serious adverse events · patients with Guillain‐Barré syndrome
1 finding from 1 review
Participants with 1 or more serious adverse events · adults with severe Guillain‐Barré syndrome (GBS disability score > 2), within 2 weeks form onset
Eculizumab showed no clear difference in participants with 1 or more serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Participants with 1 or more serious adverse events · patients with Guillain‐Barré syndrome
It is very uncertain whether interferon beta‐1a changes participants with 1 or more serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
Pain at 6 months or more; all doses Assessed by change from baseline, using a 0‐ to 100‐mm VAS, where higher scores indicate more pain) · people with diabetic peripheral neuropathy
1 finding from 1 review
Impairment of sensation Assessed by quantitative sensory testing ‐ thermal threshold ‐ at 6 months or more · the treatment of diabetic peripheral neuropathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Symptom quality and severity Assessed by NSS score (range of possible scores 0 to 9; higher scores indicate more symptoms) · the treatment of diabetic peripheral neuropathy
1 finding from 1 review
Functional impairment and disability Assessed by NIS or NDS at 6 months or more · people with diabetic peripheral neuropathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Impairment of sensation Assessed by quantitative sensory testing ‐ vibration perception threshold ‐ at 6 months or more · people with diabetic peripheral neuropathy
1 finding from 1 review
Impairment of sensation Assessed by quantitative sensory testing ‐ thermal threshold ‐ at 6 months or more · people with diabetic peripheral neuropathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Symptom quality and severity Assessed by change in symptom score on a validated screening questionnaire (NSS or MNSI) at 6 months or more · people with diabetic peripheral neuropathy
1 finding from 1 review
no estimate extracted
2 participants
GRADE not reported
Pain at 6 months or more · the treatment of diabetic peripheral neuropathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Impairment of sensation Assessed by quantitative sensory testing ‐ vibration perception threshold ‐ at 6 months or more · the treatment of diabetic peripheral neuropathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Improvement (greater than 50% of time spent) heel‐toe walking Measured by parents' perception of toe walking frequency more than 50% of the time. · children with ITW gait
It is very uncertain whether botulinum toxin plus conservative treatment changes improvement (greater than 50% of time spent) heel‐toe walking… compared with conservative treatment only (very low certainty).
1 finding from 1 review
Proportion of people whose symptoms 'improved' (long term: more than 12 weeks) · symptomatic gastroparesis
It is very uncertain whether acupuncture changes proportion of people whose symptoms 'improved' (long term: more than… compared with gastrokinetic agents (very low certainty).
1 finding from 1 review
Improvement in symptoms of gastroparesis (long term: more than 12 weeks) ‐ not measured · symptomatic gastroparesis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of people whose symptoms 'improved' (long term: more than 12 weeks) ‐ not measured · symptomatic gastroparesis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Improvement in symptoms of gastroparesis (long term: more than 12 weeks) ‐ not measured · symptomatic gastroparesis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found